Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 46 for “"mRNA-LNP"”.
-
DEVELOPMENT OF A VACCINE FOR LYME DISEASE USING THE NUCLEOSIDE-MODIFIED mRNA-LNP PLATFORM
… nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) platform to generate a Lyme disease vaccine like the successful clinical vaccines against SARS-CoV-2. Of the antigens expressed by Borrelia burgdorferi, the causative agent of Lyme disease, outer surface protein A (OspA) is the most …
-
Design, Testing, and Optimization of a Preclinical mRNA-LNP Vaccine for Hepatitis C Virus Prophylaxis
… with advances in the nucleoside-modified mRNA lipid nanoparticle (mRNA-LNP) vaccine platform. We evaluated structural and nonstructural viral proteins in our vaccine constructs, demonstrating that encoding p7 along with core (C), envelope glycoprotein 1 (E1), and envelope glycoprotein 2 …
-
AN mRNA-LNP VACCINE ENCODING RECEPTOR-BINDING DOMAIN FRAGMENTS OF TOXIN A AGAINST CLOSTRIDIUM DIFFICILE
… the cell cytoplasm, were used for the design of mRNA vaccines against C. difficile. The mRNA-encoded bacterial antigens were found to be able to successfully express in vitro in mammalian cells. Mice were injected with 3 doses of the mRNA vaccine and the immunogenicity was evaluated by ELISA for …
-
Process and Formulation Optimization of a Continuous Microfluidic-Based Platform for High-Quality mRNA-LNP Production
Messenger RNA (mRNA) has emerged as a transformative platform for vaccines and targeted therapies due to its capacity for precise and rapid gene expression. The COVID-19 pandemic underscored both its promise and the challenges of large-scale production. In response, continuous flow …
-
Growth hormone therapy accelerates recovery from sexually dimorphic acetaminophen-induced liver injury
… and EGF in hepatocytes via nucleoside-modified mRNA-LNP delivery in mice. We confirmed specific hepatotropism of mRNA-LNP via intravenous injection of firefly luciferase encoding mRNA-LNP, with protein expression lasting about 3 days. In the liver, virtually all hepatocytes were transfected …
-
Development of a Microneedle Patch for mRNA in Lipid Nanoparticles
mRNA technology offers an efficient way to develop new vaccines and therapeutics to address unmet medical needs. However, it is limited by its instability and low transfection efficiency. Lipid nanoparticles (LNPs) improve transfection and protect mRNA from enzymes in vivo but introduce more …
-
(Macro)molecular strategies for lipid nanoparticles and T cell engineering
Over the past years, the immense potential of mRNA-lipid nanoparticle (LNP) formulations has become evident, particularly with the emergence of Covid-19 vaccines. The fast, relatively simple, and scalable manufacturing process of mRNA LNP formulations played a crucial role in combatting the global …
-
Defining mRNA-generated T cell memory in respiratory viral infection
… the ability of T cells generated by novel mRNA-LNP vaccines to restrict viral infection in currently unknown. To address this, we studied antigen specific T cell memory generated by mRNA-LNP vaccines in both humans and mice. We report that functional and durable T cell memory is induced by …
-
Human primary and iPSC-derived hepatocyte cell therapies to treat liver disease
… (EGF) in hepatocytes via nucleoside-modified mRNA encapsulated in lipid nanoparticles (mRNA-LNP) in mice. We confirm specific hepatotropism of intravenous injected mRNA-LNP, with protein expression lasting about three days. In the liver, virtually all hepatocytes are transfected along with a …
-
Advancing genetic engineering of platelets towards compatibility with common blood banking practices
… of platelets by using lipid nanoparticles (LNP) to deliver exogenous cargo. Optimized LNP loaded with mRNA (mRNA-LNP) are able to engineer platelets to express reporter proteins when suspended in a non-clinical crystalloid solution. The modified platelets retained in vitro physiology, and …
-
Next-Generation Lipid Nanoparticle Formulations for Non-Liver Delivery of Nucleic Acid-Based Therapies and Vaccines
The clinical application of lipid nanoparticles (LNPs) delivering RNA-therapies has advanced remarkably over the past few decades with the Food and Drug Administration (FDA) approval of ONPATTRO® in 2018 for treating a liver genetic disease following systemic administration and the most recent …
-
Evaluating Buffer Concentrations and pH effects on LNP-mRNA stability
Messenger RNA (mRNA)-based therapeutics have demonstrated clinical success, particularly with COVID-19 vaccines, but face significant stability challenges that limit broader application. mRNA-LNP formulations require ultra-cold storage (-60 to -80°C) due to susceptibility to pH-dependent hydrolytic …
-
DEVELOPMENT AND COMPARISON OF VSV AND MRNA VACCINES FOR MACHUPO VIRUS
… of MACV-specific T cells. Next, we created mRNA-LNP-based vaccines for MACV. The first mRNA-LNP vaccine, MACV mRNA, expresses the full-length MACV GPC. The second mRNA-LNP vaccine, called MACV VLP mRNA, encodes MACV GPC with appended sequences that induce the budding of virus-like particles …
-
The Effect Of Maternal Antibodies On Anti-Viral Immunity In Infant Mice
… show that a novel vaccine, nucleoside-modified mRNA encapsulated in lipid nanoparticles (mRNA-LNP) encoding influenza hemagglutinin, overcomes maternal antibody inhibition by prolonged establishment of germinal centers. mRNA-LNP vaccination offers a promising means of eliciting protective immune …
-
Optimizing systems to enable genetic engineering of transfusable platelets
… lipid nanoparticles containing mRNA (mRNA-LNP) enable exogenous protein expression in human and rat platelets. Exogenous protein expression did not appear to require, nor correlate with platelet activation. Transfected platelets retained hemostatic function and accumulated in …
-
Design and Immunogenicity of Stabilized HIV-1 Modified Messenger RNA Vaccines
… development.</p><p>Nucleoside modified, purified mRNA in lipid nanoparticles (mRNA–LNP) has emerged as a novel vaccine platform. The success of using mRNA–LNP forvaccines was demonstrated first by an experimental Zika vaccine and then by two clinically approved COVID-19 vaccines. mRNA vaccine is …
-
BPTF-Dependent Regulation of Vaccine-Induced B Cell Responses
… biology and vaccine-induced GC B cell responses. mRNA-lipid nanoparticle (LNP) vaccines are a powerful technology capable of inducing robust B cell responses in both humans and mice. In mice, mRNA-LNP vaccines have the potential to be a useful tool in generating vaccine-induced populations of …
-
Enhancing SARS-CoV-2 DNA Vaccines with CD40 Ligand and Lipid Nanoparticle Delivery
… and vaccine-induced immunity. Although mRNA vaccines induce strong early responses, serum neutralizing antibody (NAb) titers often wane substantially within 7–9 months post-vaccination, increasing susceptibility to breakthrough infection. While updated, variant-matched boosters can …
-
Investigating potency and efficacy of mRNA lipid nanoparticle systems and targeting lymph node
mRNA lipid nanoparticle (LNPs) based vaccines played a crucial role in dealing with the COVID19 pandemic. The primary function of LNPs is to encapsulate and deliver mRNA to the target site, facilitating its release into the cytosol, thereby eliciting an immune response against the antigen …
-
Investigating the critical quality attributes of mRNA-loaded lipid nanoparticles and their biomolecular corona using novel analytical pipelines
Lipid nanoparticles (LNPs) have emerged as a promising platform for messenger RNA (mRNA) encapsulation, as demonstrated by their pivotal role during the coronavirus disease 2019 (COVID-19) pandemic. Despite the availability of several mRNA vaccines on the market and ongoing clinical trials, …
Page 1 of 3